SKAN : Investor Presentation January 2023

SKAN Group Investor Presentation

January 2023

Disclaimer

SKAN

THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.

This presentation ( the "Presentation"), contains information regarding SKAN Group AG (the "Company") and each of its subsidiaries and affiliates (the "Group"). The information and opinions contained in this Presentation do not purport to be comprehensive and are provided as at the date of this Presentation or as of the date specified herein. Certain financial information (including percentages) in this Presentation may have been rounded according to commercial standards. As a result, the aggregate amounts may not correspond in all cases to the aggregated amounts of the underlying (unrounded) figures appearing elsewhere in this Presentation.

The financial information presented herein has been prepared in accordance with Swiss GAAP FER. Certain financial data included in this Presentation consists of non-Swiss GAAP FER financial measures. These non-Swiss GAAP FER financial measures may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other financial measures determined in accordance with Swiss GAAP FER. In addition, certain financial information contained herein has not been audited, confirmed or otherwise covered by a report by independent accountants and, as such, actual data could vary, possibly significantly, from the data set forth herein. None of the Company, the Group, and any other person is under any obligation to update or keep current the information contained in this Presentation or to correct any inaccuracies which may become apparent, and any opinions expressed herein are subject to change without notice.

Statements made in this Presentation may include forward-looking statements. These statements may be identified by the fact that they use words such as "anticipate", "estimate", "should", "expect", "guidance", "project", "intend", "plan", "believe", "will", "could" and/or other words and terms of similar meaning in connection with, among other things, any discussion of results of operations, financial condition, liquidity, prospects, growth, strategies or developments in the industry in which we operate. Such statements are based on management's current intentions, expectations or beliefs and involve inherent risks, assumptions and uncertainties, including factors that could delay, divert or change any of them. Forward-looking statements contained in this Presentation regarding trends or current activities should not be taken as a representation that such trends or activities will continue in the future. Actual outcomes, results and other future events may differ materially from those expressed or implied by the statements contained herein. Such differences may adversely affect the outcome and financial effects of the plans and events described herein and may result from, among other things, changes in economic, business, competitive, technological, strategic or regulatory factors and other factors affecting the business and operations of the company. Neither the Company nor any of their subsidiaries or affiliates are under any obligation, and each such entity expressly disclaims any such obligation, to update, revise or amend any forward-looking statements, whether as a result of new information, future events or otherwise.

Further, this Presentation may include market share and industry data obtained by the Company from industry publications and market surveys. The Company may not have access to the facts and assumptions underlying the numerical data, market data and other information extracted from public sources and neither the Company, the Group, nor any of their respective directors, officers , employees, shareholders, affiliates, agents and advisers are able to verify such information, and assume no responsibility for the correctness of any such information.

This Presentation does not constitute or form part of, and should not be construed as, an offer or invitation or inducement to subscribe for or otherwise acquire, any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Group, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This Presentation does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). Neither the Company nor any other member of the Group has registered or intends to register any securities under the Securities Act or the securities laws of any state or other jurisdiction of the United States.

THIS PRESENTATION IS NOT AN INVITATION TO PURCHASE SECURITIES OF THE COMPANY OR THE GROUP.

January 2023

SKAN Group AG Investor Presentation

2

Key challenge for (bio-)pharmaceutical products

SKAN

Key challenge:

Medical safety

Medication safety is key and (cross-) contamination unacceptable

Key contamination sources:

Air particles

Input: Raw materials, containers, closures

Personnel

Products:

Injectables

Cancer drugs (ADC, Cytotoxics)

Cell & gene therapy (Advanced Therapy Medicinal Products (ATMPs))

Hormones: Insulin

Medical drugs (Thrombosis, EPO, blood plasma products, botox, etc.)

Vaccines: Flu, COVID-19, etc.

Increased infection risk as their application bypasses many of the human body's natural defenses

In particular true for:

High-value biopharma drugs

Risk of significant economic

losses if high-value biopharma drugs get contaminated

Risk of cross-contamination

increases with small batch size of fast-growing personalized medicine

January 2023

SKAN Group AG Investor Presentation

3

Century of biology: Shift toward injectable biotech drugs drives need for aseptic process solutions

SKAN

Top 10 medicines 2005

Lipitor	Zoloft
Pfizer	Pfizer
Nexium	Plavix
Astra Zeneca	Sanofi
Prevacid	Efexor
Takeda	Pfizer
Lipitor	Singulair
Pfizer	MSD
Adavair Diskus	Norvasc
GSK	MSD

January 2023

Top 10 medicines 2020

Eylea

Regeneron, Bayer

2020 Sales: $8.36 Mia.

Keytruda

Merck & Co.

2020 Sales: $14.38 Mia.

Revlimid

Bristol Myers

Squibb

2020 Sales: $12.15 Mia.

Eliquis

Bristol Myers Squibb,

Pfizer

2020 Sales: $9.17 Mia.

Imbruvica

AbbVie, Johnson

& Johnson

2020 Sales: $8.43 Mia.

mAb / biotech drug substance

Humira

AbbVie

2020 Sales: $20.39 Mia.

Stelara

Johnson & Johnson

2020 Sales: $7.94 Mia.

Opdivo

Bristol Myers Squibb

2020 Sales: $7.92 Mia.

Biktarvy

Gilead Sciences

2020 Sales: $7.26 Mia.

Xarelto

Bayer, Johnson &

Johnson

2020 Sales: $6.93 Mia.

4

Isolators - Mission critical for (bio-)pharmaceutical processes

SKAN

Solution: Medication sterility

Traditional pharma

Pharma products mainly chemical based

Cleanroom

• Filling / closing in cleanroom with terminal sterilization

• Inappropriate for complex biopharmaceuticals

Raw materials procurement

CleanroomTerminal

environmentsterilisation

Formulation	Fill-finish	Quality
control

Sterilisation Aseptic processing

Packaging & shipping

Biopharma of today and tomorrow

New products mainly biotech- based (sensitive to heat and pressure)

Isolators

• Filling/closing under aseptic conditions eliminating effectively all contamination risk
• Reduced cleanroom footprint and running costs and environmental-friendly
• Complex process results in high market entry barriers

January 2023

SKAN Group AG Investor Presentation

Note: SAL = Sterility Assurance Level.

5